Business news, market intelligence, and global industry analysis.
The Latest

Dr. Reddy’s Laboratories launches sorafenib generic in US

bySrinath
June 14, 2022
Total
0
Shares
0
0
0

Dr. Reddy’s Laboratories said that it has launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg in the US market following the approval of the US Food and Drug Administration (FDA).

Dr. Reddy’s Sorafenib Tablets, USP, 200 mg is a generic of Bayer HealthCare Pharmaceuticals’ cancer drug Nexavar (sorafenib). The product will be available in 200 mg tablets in bottle count sizes of 120, said Dr. Reddy’s Laboratories.

Dr. Reddy’s Laboratories launches sorafenib generic in US
Dr. Reddy’s Laboratories launches sorafenib generic in US. Photo courtesy of Karthikndr/Wikimedia Commons.

Marc Kikuchi — Dr. Reddy’s Laboratories North America Generics CEO said: “We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients.”

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Satsuma doses first patient in EMERGE clinical trial of STS101 in migraine

US biopharma company Satsuma Pharmaceuticals has dosed the first patient in its phase 3 EMERGE clinical trial of STS101 (dihydroergotamine (DHE) nasal powder) for migraine treatment. The EMERGE efficacy trial is a single-dose, double-blind, randomized, placebo-controlled, parallel-group study to be held in multiple centers. The phase 3 clinical trial will feature nearly 1,140 migraine patients […]

The post Satsuma doses first patient in EMERGE clinical trial of STS101 in migraine appeared first on PharmaNewsDaily.com.

bypharmanewsdaily